As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...

R&D innovation is likely to remain a major focus area in 2025 . M&A activity is also expected to remain strong, particularly with Trump’s return to the White House.Regular pipeline setbacks, slow ramp ...